HEIDI VIDAL: Open Payments
NPI 1942367032 · WOODBURY, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,431 in 76 payments from 9 companies in 2025. Trend: 2023 $1,449 · 2024 $1,144 · 2025 $1,431
Food & beverage: $1,321Education: $109
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $452 |
| Teva Pharmaceuticals USA, Inc. | 17 | $302 |
| Neurocrine BioSciences, Inc. | 14 | $238 |
| Otsuka America Pharmaceutical, Inc. | 13 | $237 |
| Alkermes, Inc. | 4 | $73 |
| E.R. Squibb & Sons, L.L.C. | 4 | $62 |
| Janssen Pharmaceuticals, Inc | 2 | $29 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $18 |
Products named: VRAYLAR, INGREZZA, REXULTI, AUSTEDO XR, ARISTADA, COBENFY, ABILIFY ASIMTUFII, UZEDY.
Industry payments across NJ — which companies pay providers there.
